Senior Immunology Scientist: Pathogenic Cell Depletion

BioSpace; Cambridge (MA); On-site; USD 120,000 - 170,000; Full time

Job summary

AbbVie seeks a Senior Scientist I in Immunology Discovery to conceive and implement novel experimental approaches addressing key questions in immune cell depletion. The role involves hands-on translational in vitro and ex vivo assays, PK/PD assessments, and collaboration across in vivo pharmacology, DMPK, and technology groups.

The position supports IND-enabling and early-stage discovery programs, with emphasis on autoimmune disease efficacy models and receptor occupancy studies.

Qualifications

• Advanced immunology knowledge with hands-on research experience.
• Experience in autoimmune disease biology or pathogenic immune cell depletion is preferred.
• Ability to design, execute, and troubleshoot complex experiments independently.
• Strong scientific communication and meticulous documentation practices.

Responsibilities

• Conduct novel experimental approaches to address key questions in immune cell depletion.
• Collaborate with cross-functional teams to integrate results across projects.
• Design and perform immunological assays and complex cellular systems analyses.
• Apply PK/PD concepts and advanced analytics to quantify biomarkers.

Skills

Immunology knowledge

Cell biology

Autoimmune disease biology

Experimental design

Scientific communication

Cross-functional collaboration

Adaptability

Education

Immunology degree (BSc/ MSc/ PhD)

Tools

Multi-color flow cytometry

Cytokine assays

Digital PCR (ddPCR)

qPCR

RNA extraction

Live cell imaging (Incucyte/xCELLigence)

Bioinformatics / Computational biology

Job description

AbbVie seeks a Senior Scientist I in Immunology Discovery to conceive and implement novel experimental approaches addressing key questions in immune cell depletion. The role involves hands-on translational in vitro and ex vivo assays, PK/PD assessments, and collaboration across in vivo pharmacology, DMPK, and technology groups.

The position supports IND-enabling and early-stage discovery programs, with emphasis on autoimmune disease efficacy models and receptor occupancy studies.